U.S. Markets close in 2 hrs 26 mins

Acorda Therapeutics, Inc. (ACOR)

NASDAQ Global Select - NASDAQ Global Select Real Time Price. Currency in USD
Add to watchlist
22.75+0.90 (+4.12%)
As of 1:34PM EDT. Market open.
People also watch
AMAGALNYACADBMRNSGEN

Acorda Therapeutics, Inc.

420 Saw Mill River Road
Ardsley, NY 10502
United States
914-347-4300
http://www.acorda.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees597

Key Executives

NameTitlePayExercisedAge
Dr. Ron Cohen M.D.Founder, Chief Exec. Officer, Pres and Director1.34M1.03M61
Mr. David Lawrence M.B.A.Chief of Bus. Operations and Principal Accounting Officer623.05k8.29k59
Ms. Jane Wasman J.D.Pres of International, Gen. Counsel and Corp. Sec.900.13k52.13k61
Mr. Andrew Asa Hindman M.B.AChief Bus. Devel. Officer707.83kN/A44
Dr. Burkhard Blank M.D.Chief Medical Officer1.09MN/A62
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinson’s disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinson’s disease; SYN120, which is in Phase II clinical trial to treat Parkinson’s disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women’s Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Corporate Governance

Acorda Therapeutics, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 5. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 7; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.